Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Koithan

Psychiatry Des Moines, IA Doctor of Osteopathy

NPI 1235194143 CMS profile 283129

2500 82 Pl, Wadle And Associates Pc, Des Moines, IA 50322

Open in the dashboard

General payments

$8,613

250 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Koithan of Des Moines, IA is reported in the CMS Open Payments database as having received $8,613 across 250 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $642 34
2024 General $2,963 29
2023 General $3,318 27
2022 General $589 44
2021 General $596 50
2020 General $319 44
2019 General $185 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Koithan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Thomas Koithan were reported at $642. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Thomas Koithan Psychiatry median Middle half National median
2019 $185 $184 $59–$605 $163
2020 $319 $119 $36–$372 $114
2021 $596 $143 $43–$576 $132
2022 $589 $153 $50–$590 $149
2023 $3,318 $170 $56–$651 $160
2024 $2,963 $179 $57–$673 $164
2025 $642 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $2,928 4 payments
  2. Brainsway USA Inc $2,467 2 payments
  3. AbbVie, Inc. $711 51 payments
  4. Neos Therapeutics, LP $586 70 payments
  5. Allergan Inc. $295 34 payments
  6. Otsuka America Pharmaceutical, Inc. $267 14 payments
  7. Almatica Pharma LLC $153 14 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $151 8 payments
  9. Ironshore Pharmaceuticals Inc. $148 8 payments
  10. Lundbeck LLC $125 7 payments
  11. Other $782 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,925 245 payments
  2. Travel and Lodging $1,599 2 payments
  3. Education $90 3 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $2,928 4 payments
  2. Brainsway Deep TMS System $2,448 1 payment
  3. VRAYLAR Neuroscience $564 43 payments
  4. VRAYLAR Neuroscience $442 42 payments
  5. Adzenys XR-ODT Adhd $426 42 payments
  6. REXULTI $267 14 payments
  7. COTEMPLA XR-ODT $217 41 payments
  8. Adzenys XR-ODT Adhd $144 27 payments
  9. LOREEV XR $137 12 payments
  10. TRINTELLIX $117 6 payments
  11. Other $1,500 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

337

Median for Psychiatry & Neurology: 100

Drug cost

$4,673

Median for Psychiatry & Neurology: $2,986

Branded share of claims

14.5%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bupropion Xl Bupropion Hcl Brand 38 $1,196
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 11 $793
Aripiprazole Generic 11 $457
Trazodone Hcl Generic 37 $328
Buspirone Hcl Generic 17 $290
Escitalopram Oxalate Generic 43 $283
Alprazolam Generic 42 $267
Zolpidem Tartrate Generic 22 $244
Lorazepam Generic 33 $230
Clonazepam Generic 28 $190

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $154
$154 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $99
$99 — —
REXULTI
  • Lundbeck LLC $48
  • Otsuka America Pharmaceutical, Inc. $43
$92 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $71
$71 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

250 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record